Interstitial Lung DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Interstitial Lung Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Taubman Center
Director of the Michigan Medicine Interstitial Lung Disease program, Vice-Chair of the Medical School Institutional Review Board for Human Subjects Research, Associate Program Director Internal Medicine Residency Program - Research, Co-Director University of Michigan Medical School Scientific Discovery Pathway, Steering committee chair for the pulmonary fibrosis foundations Care Center Network and Patient Registry. Dr. Flaherty is rated as an Elite provider by MediFind in the treatment of Interstitial Lung Disease. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Flaherty is board certified in Pulmonary Disease.
Johns Hopkins Bayview Medical Center
Dr. Danoff is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and Co-Director of the Hopkins Interstitial Lung Disease Clinic. She is a specialist in diseases causing fibrosis or scarring in the lung, particularly those associated with autoimmune diseases including myositis. Dr. Danoff is rated as an Elite provider by MediFind in the treatment of Interstitial Lung Disease. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Lung Transplant, and Endoscopy. Dr. Danoff is board certified in American Board Of Internal Medicine.
UPMC Comprehensive Lung Center - Simmons Center
Kevin Gibson, MD, specializes in interstitial lung disease and is board-certified in pulmonary disease and internal medicine by the American Board of Internal Medicine. He practices at UPMC Comprehensive Lung Center - Simmons Center and is affiliated with University of Pittsburgh Physicians, Department of Medicine and UPMC Presbyterian. Dr. Gibson completed his medical degree at University of Medicine and Dentistry of New Jersey, residency at Emory University School of Medicine, and fellowship at the University of Pittsburgh School of Medicine.Dr. Gibson specializes in treating patients with idiopathic pulmonary fibrosis, sarcoidosis, autoimmune lung disease, and occupational lung disease. Dr. Gibson is rated as an Elite provider by MediFind in the treatment of Interstitial Lung Disease. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Lung Transplant. Dr. Gibson is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Gibson is currently accepting new patients.
Summary: MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see if low doses of the hormone drug danazol can help.